PappKALangleyRGLebwohlM. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371(9625):1675–1684.
2.
LangleyRGElewskiBELebwohlM. Secukinumab in plaque psoriasis—results of two phase 3 trials. N Engl J Med. 2014;371(4):326–338.
3.
YosipovitchGGoonAWeeJChanYHGohCL. The prevalence and clinical characteristics of pruritus among patients with extensive psoriasis. Br J Dermatol. 2000;143(5):969–973.
4.
LjosaaTMStubhaugAMorkCMoumTWahlAK. Improvement in Psoriasis Area and Severity Index score predicts improvement in skin pain over time in patients with psoriasis. Acta Derm Venereol2013;93(3):330–334.
5.
Stein GoldLBagelJLebwohlM. Efficacy and safety of apremilast in systemic- and biologic-naive patients with moderate plaque psoriasis: 52-week results of UNVEIL. J Drugs Dermatol. 2018;17(2):221–228.
6.
KavanaughAGottliebABMoritaA. The contribution of skin and joint improvements to the health-related quality of life of patients with active psoriatic arthritis [Abstract 2539]. Arthritis Rheumatol. 2017;69(suppl 10).
7.
NPF Survey2014. Data from 470 moderate Ps patients; exception areas are face, hands, palms, soles, genitalia. (unpublished data)
8.
NPF Survey data 2014. Moderate psoriasis patient satisfaction on non-biologics—extremely dissatisfied or somewhat dissatisfied with current therapy. (unpublished data).
9.
AbuabaraKWanJTroxelAB. Variation in dermatologist beliefs about the safety and effectiveness of treatments for moderate-to-severe psoriasis. J Am Acad Dermatol. 2013;68(2):262–269.
10.
van der HeijdeDGladmanDDKishimotoM. Efficacy and safety of ixekizumab in patients with active psoriatic arthritis: 52 week results from a phase III study. J Rheumatol. 2018;45(3):367–377.
